The PPV of an MR-proANP concentration ≥120 pmol/L was also heterogeneous with lower PPV in patients without prior heart failure [53.1% (44.1–62.0%)] or atrial fibrillation [59.5% (54.2–64.6%)], and in those with COPD [50.0% (40.7–59.3%)] (see Supplementary material online, Figure S2). This evidence concerns the gene NPPA and heart failure.